The Impact of Price-cap Regulations on Entry and Exit by Generic Pharmaceutical Firms in Canada

Pharmaceutical markets Canada are unique in that generic drugs are subject to 'price-cap' regulations set by provincial governments. 
 
Canada's largest pharmaceutical market, the province of Ontario, has been a leader in setting generic price-cap regulations in relation to the price of the brand-name drug, and has since the early 1990s adopted progressively lower price-caps. 
 
Dr. Aslam Anis will report the results of studies describing the impact of the latest wave of price-caps instituted in Canadian provinces since 2010, including Ontario's regulation requiring generic drugs to be sold at 25% of the brand-name product's price, the lowest price-cap in Canada's history. 
 
Dr. Aslam Anis is a renowned Canadian health economist. He is a Professor of Health Economics in the School of Population and Public Health, University of British Columbia, the Director of Vancouver's Centre for Health Evaluation and Outcome Sciences, and National Director of the CIHR Canadian HIV Trials Network.
 
The seminar will be held in the Sir Alexander Fleming room, 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT. A buffet lunch will be available from 12:00 noon. The seminar will start promptly at 12.30 pm and finish promptly at 2.00 pm.
 
View the full invite here.
Monday, 23 February 2015